IEX •
Healthcare •
Biotechnology •
Quote as of 06/12/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization180.97 mln
Float94.02 mln
Earnings Date07/30/2026
Piotroski F-Score
1
/ 9
Very weak
Beneish M-Score
-3.09
Reliable
1-Year Forecast
3.10
Transformational upside
Relative Strength
2
/ 100
Severely lagging
Debt / Equity
3.33
Highly leveraged
ROE
-237
Deeply negative
Business Description
Alector is a US-based clinical-stage company focused on developing treatments that slow or stop diseases that cause the brain and nervous system to break down. Its portfolio includes several experimental medicines targeting Alzheimer's disease, Parkinson's disease, Lewy body dementia, and related conditions, spanning both early research and active clinical testing. The company works alongside GlaxoSmithKline to advance a group of treatments designed to raise levels of a protective brain protein called progranulin. Founded in 2013 and based in South San Francisco, Alector continues to build on its research pipeline with the goal of bringing meaningful options to patients with limited treatment choices.
